
Advac LLC Profile last edited on: 10/29/19
CAGE: 7RVK1
UEI: PJPNK66DNNZ9
Business Identifier: Safer, more effective vaccine for human respiratory syncytial virus (RSV) Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
873 Misty View Court
Lilburn, GA 30047
Lilburn, GA 30047
(770) 686-8255 |
N/A |
N/A |
Location: Single
Congr. District: 04
County: Gwinnett
Congr. District: 04
County: Gwinnett
Public Profile
Advac, LLC is a start-up vaccine research company currently focused on development of a safer, more effective vaccine for human respiratory syncytial virus (RSV) - common respiratory virus that can cause serious complications in infants and older adults. The leading cause of hospitalization among infants in the US, there is no FDA-approved vaccination for RSV. The firm is addressing assessmentof the safety and efficacy of two promising vaccines that would not induce enhanced respiratory disease - one using an inactivated split virusâa virus that is killed with chemicals, then split apartârather than an inactivated whole virus; the other involving vaccines containing virus-like particles (VLP), which are engineered to resemble viruses but do not contain the viral genome. The latter seems to offer protection against RSV by controlling the replication of the virus in the lungs without causing detectable enhanced respiratory disease. Also being evaluated is a unique adjuvant, a substance that enhances the bodyâs immune response to the vaccine and improves its effective
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2020 | 1 | NIH | $272,223 | |
Project Title: Multi Na-Based Influenza Vaccines | ||||
2018 | 1 | NIH | $225,000 | |
Project Title: New Rsv Vaccines with Improved Safety and Efficacy |
Key People / Management
Sang-Moo Kang